ps20 stabilizing agent  (BioTherapeutics Inc)

Journal: Pharmaceutics

Article Title: Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates

doi: 10.3390/pharmaceutics14122575

Figure Lengend Snippet: Type and content of the fatty acids present in PS20 and PS80 raw material [ 98 , 99 ].

Article Snippet: To achieve such desirable stabilizing effects, PS20 and PS80 are often used in the formulation of the protein drugs in a concentration range of 0.003–3 mg/mL based on the Physicians Desk Reference [ ]. provides an overview of the FDA and CBER (Center for Biologics Evaluation and Research)-approved protein biotherapeutics stabilized with PSs, also indicating the concentration of the surfactant.

Techniques: Raw Material

Journal: Pharmaceutics

Article Title: Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates

doi: 10.3390/pharmaceutics14122575

Figure Lengend Snippet: Summary of the available information on the potential alternatives to PSs for the stabilization of protein biotherapeutic formulations.

Article Snippet: To achieve such desirable stabilizing effects, PS20 and PS80 are often used in the formulation of the protein drugs in a concentration range of 0.003–3 mg/mL based on the Physicians Desk Reference [ ]. provides an overview of the FDA and CBER (Center for Biologics Evaluation and Research)-approved protein biotherapeutics stabilized with PSs, also indicating the concentration of the surfactant.

Techniques: Adsorption, Immunopeptidomics, Blocking Assay, Concentration Assay, Formulation, Injection, Solvent, Binding Assay, Lyophilization, Bacteria